Catalent completes $30m modernisation at Limoges facility

17-Mar-2022

A small-to-mid-scale flexible filling line has been installed, capable of handling vials, syringes or cartridges under barrier isolator technology

Catalent, a service provider for biopharma, cell, gene, and consumer health partners, has announced the completion of a $30m project at its facility in Limoges, France, to develop its biopharmaceutical development, drug product fill/finish services, and packaging.

The site will further expand Catalent Biologics’ global network, with early phase integrated clinical development through to clinical supply services and small-scale commercial manufacturing, allowing tech transfer of projects as they progress to late-stage and larger-scale commercial supply from other manufacturing facilities in Europe and North America.

The project has seen a modernisation of the site, enabling it to handle large molecule programmes, with additional capacity for small molecule injectable dosage form development. A small-to-mid-scale flexible filling line has been installed, capable of handling vials, syringes or cartridges under barrier isolator technology, and enhancements have been made to analytical and quality control laboratories, supporting clinical packaging, cold storage, and regulatory capabilities. The company says the expansion will create up to 80 additional jobs at the site.

Sign up for your free email newsletter

“This investment has transformed the Limoges site into a world-class facility to support the development of early phase and small-scale commercial biologic drugs, and offers customers integrated services to accelerate programs towards and through the clinic, and ultimately to market. Even prior to completion, multiple clinical and commercial customers have already signed contracts for programs to be undertaken at the site,” said Mike Riley, Catalent’s President, Biotherapeutics. “Limoges will now work closely with other Catalent facilities in Europe and the US to provide globally integrated solutions for a range of therapies.”

Companies